OIA Response: Adalimumab and etanercept data
Request dated 23 May 2019 for information relating to treatment of ulcerative colitis and crohn’s disease.
18 June 2019
[Name and contact details redacted]
Kia ora [Name redacted]
REQUEST FOR INFORMATION
Thank you for your request dated 23 May 2019 under the Official Information Act 1982 (OIA) for information relating to ulcerative colitis and crohn’s disease. You asked for:
- Given the high level of interest in Entyvio, would it be possible for you to share recent treatment data?
The Therapeutic Group Manager, Matt Tyson, has explained that you were wanting data on adalimumab and etanercept. Matt is happy to answer any questions about the data provided.
The attached data spreadsheet [XLSX, 26 KB] was recently released under the OIA for another requestor. It includes the information you have requested along with information on secukinumab and infliximab.
Where a patient may be identified due to low patient numbers, the information provided has been stated as ‘0-10’. For your request, this applies to the data for pyoderma gangrenosum and adult-onset Still’s disease.
Accordingly, we have withheld a small amount of information from the spreadsheet as we consider this is necessary to protect the privacy of natural persons (section 9(2)(a) of the OIA).
As required under the OIA, we also considered whether, in the circumstances, the withholding of the information stated above was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.
We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
[Alison Hill's signature]
Director, Engagement and Implementation